Navigating Pharmaceutical Investment Risks

This chapter explores the challenges and uncertainties involved in pharmaceutical investments, particularly the competitive dynamics surrounding the PDUFA date for miradimetinib against AstraZeneca's Kosalugo. It highlights the disparities in resources between smaller companies and larger firms, along with a comparison of clinical data regarding efficacy and tolerability.